Published in Oncoimmunology on October 14, 2016
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep (2014) 4.97
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res (2006) 2.56
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer (2009) 1.92
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
[Cloning and identification of cDNA fragments related to human esophageal cancer]. Zhonghua Zhong Liu Za Zhi (1998) 1.51
Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res (2007) 1.50
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol (2003) 1.37
Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res (2010) 1.28
Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 1.28
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA₂-IIA expression in astrocytes and microglia. J Neuroinflammation (2011) 1.16
Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res (2009) 1.15
The controversial role of microglia in malignant gliomas. Clin Dev Immunol (2013) 1.11
Cell-specific processing and release of the hormone-like precursor and candidate tumor suppressor gene product, Ecrg4. Cell Tissue Res (2012) 1.06
Processing of proaugurin is required to suppress proliferation of tumor cell lines. Mol Endocrinol (2011) 1.06
Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS One (2009) 1.05
STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res (2014) 1.04
ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo. Oncol Lett (2013) 1.01
Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages. J Leukoc Biol (2012) 0.99
Augurin stimulates the hypothalamo-pituitary-adrenal axis via the release of corticotrophin-releasing factor in rats. Br J Pharmacol (2010) 0.97
Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol (2014) 0.83